April 17, 2025 06:45 AM EDT
R&D

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Max Gelman

Senior Editor

Eli Lil­ly re­port­ed the first Phase 3 da­ta for its oral GLP-1 or­for­glipron Thurs­day morn­ing, say­ing the drug suc­ceed­ed in a type 2 di­a­betes tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

In a blow to its obe­si­ty pipeline, Pfiz­er drops oral drug af­ter liv­er in­jury case

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

What's Pfiz­er's next move af­ter shelv­ing its oral obe­si­ty drug danuglipron?

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times